Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
18
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Wachter Paul | Director | 21 | $0 | $950.5K | 2016-02-29 |
| Swartzburg Michael | Principal Accounting Officer | 1 | $0 | $0 | 2016-02-12 |
| Braun Shirley | VP, Human Resources | 2 | $0 | $0 | 2016-02-12 |
| Rubio Roman G. | SVP, Translational Medicine | 6 | $0 | $0 | 2016-02-12 |
| Schwartz Steven Daniel | Director | 17 | $0 | $7.60M | 2016-02-12 |
| Barone Samuel B. | Chief Medical Officer | 5 | $0 | $0 | 2016-02-12 |
| Gasmi Mehdi | VP, Pharmaceutical Development | 28 | $0 | $516.9K | 2016-02-12 |
| Blumenkranz Mark S. | Director | 38 | $0 | $8.43M | 2016-02-12 |
| MCLAUGHLIN JOHN PETER | Director | 9 | $0 | $0 | 2016-02-12 |
| Cleveland Paul B | President and CEO | 1 | $0 | $0 | 2015-12-09 |
| Hull Hans | SVP, Legal and Corp. Dev. | 15 | $0 | $1.22M | 2015-08-21 |
| Bain Linda | Chief Financial Officer | 6 | $0 | $79.0K | 2015-08-21 |
| Chalberg Thomas W. | Chief Executive Officer | 13 | $0 | $5.46M | 2015-05-05 |
| Zygtech, LLC | 10% Owner | 9 | $0 | $6.53M | 2015-04-14 |
| REGENERON PHARMACEUTICALS INC | 10% Owner | 5 | $10.00M | $0 | 2014-08-05 |
| VHCP Co-Investment Holdings II, LLC | 10% Owner | 3 | $6.80M | $0 | 2014-08-05 |
| Hove Anders D | 10% Owner | 3 | $6.80M | $0 | 2014-08-05 |
| Deerfield Special Situations Fund, L.P. | 10% Owner | 27 | $31.92M | $0 | 2014-08-05 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Wachter Paul | Director | A Award | 2016-02-29 | 2016-03-02 | 3,907 | — | $0 | 31,951 | SEC↗ |
| Barone Samuel B. | Chief Medical Officer | A Award deriv | 2016-02-12 | 2016-02-17 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Rubio Roman G. | SVP, Translational Medicine | A Award deriv | 2016-02-12 | 2016-02-17 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Gasmi Mehdi | Chief Scientific Officer | A Award deriv | 2016-02-12 | 2016-02-17 | 188,000 | — | $0 | 188,000 | SEC↗ |
| Wachter Paul | Director | A Award deriv | 2016-02-12 | 2016-02-17 | 11,905 | — | $0 | 11,905 | SEC↗ |
| Blumenkranz Mark S. | Director | A Award deriv | 2016-02-12 | 2016-02-17 | 11,905 | — | $0 | 11,905 | SEC↗ |
| Schwartz Steven Daniel | Director | A Award deriv | 2016-02-12 | 2016-02-17 | 11,905 | — | $0 | 11,905 | SEC↗ |
| MCLAUGHLIN JOHN PETER | Director | A Award deriv | 2016-02-12 | 2016-02-17 | 11,905 | — | $0 | 11,905 | SEC↗ |
| Braun Shirley | VP, Human Resources | A Award | 2016-02-12 | 2016-02-17 | 116,900 | — | $0 | 161,140 | SEC↗ |
| Swartzburg Michael | Principal Accounting Officer | A Award | 2016-02-12 | 2016-02-17 | 36,900 | — | $0 | 82,113 | SEC↗ |
| Barone Samuel B. | Chief Medical Officer | A Award | 2016-02-12 | 2016-02-17 | 50,000 | — | $0 | 91,603 | SEC↗ |
| Rubio Roman G. | SVP, Translational Medicine | A Award | 2016-02-12 | 2016-02-17 | 50,000 | — | $0 | 165,650 | SEC↗ |
| Gasmi Mehdi | Chief Scientific Officer | A Award | 2016-02-12 | 2016-02-17 | 125,000 | — | $0 | 161,803 | SEC↗ |
| Wachter Paul | Director | A Award | 2016-02-12 | 2016-02-17 | 8,333 | — | $0 | 28,044 | SEC↗ |
| Blumenkranz Mark S. | Director | A Award | 2016-02-12 | 2016-02-17 | 8,333 | — | $0 | 531,322 | SEC↗ |
| Schwartz Steven Daniel | Director | A Award | 2016-02-12 | 2016-02-17 | 8,333 | — | $0 | 376,264 | SEC↗ |
| MCLAUGHLIN JOHN PETER | Director | A Award | 2016-02-12 | 2016-02-17 | 8,333 | — | $0 | 10,333 | SEC↗ |
| Wachter Paul | Director | A Award | 2016-01-29 | 2016-02-01 | 3,334 | — | $0 | 19,711 | SEC↗ |
| Wachter Paul | Director | A Award | 2015-12-31 | 2016-01-04 | 2,101 | — | $0 | 16,377 | SEC↗ |
| Cleveland Paul B | President and CEO | A Award deriv | 2015-12-09 | 2015-12-11 | 910,000 | — | $0 | 910,000 | SEC↗ |
| Wachter Paul | Director | A Award | 2015-11-30 | 2015-12-02 | 1,909 | — | $0 | 14,276 | SEC↗ |
| Wachter Paul | Director | A Award | 2015-10-30 | 2015-11-02 | 2,373 | — | $0 | 12,367 | SEC↗ |
| Wachter Paul | Director | A Award | 2015-09-30 | 2015-10-02 | 2,428 | — | $0 | 9,994 | SEC↗ |
| Braun Shirley | VP, Human Resources | A Award | 2015-09-21 | 2015-09-23 | 3,500 | — | $0 | 44,240 | SEC↗ |
| Wachter Paul | Director | A Award | 2015-09-09 | 2015-09-11 | 5,566 | — | $0 | 7,566 | SEC↗ |
| Bain Linda | Chief Financial Officer | A Award | 2015-08-21 | 2015-08-25 | 32,930 | — | $0 | 41,930 | SEC↗ |
| Rubio Roman G. | SVP, Translational Medicine | A Award | 2015-08-21 | 2015-08-25 | 108,650 | — | $0 | 115,650 | SEC↗ |
| Barone Samuel B. | Chief Medical Officer | A Award | 2015-08-21 | 2015-08-25 | 33,960 | — | $0 | 40,960 | SEC↗ |
| Gasmi Mehdi | Chief Scientific Officer | A Award | 2015-08-21 | 2015-08-25 | 29,160 | — | $0 | 36,160 | SEC↗ |
| Hull Hans | Chief Executive Officer | A Award | 2015-08-21 | 2015-08-25 | 117,590 | — | $0 | 137,210 | SEC↗ |
| Hull Hans | SVP, Business Operations | M Exercise deriv | 2015-06-12 | 2015-06-16 | 8,300 | — | $0 | 12,200 | SEC↗ |
| Hull Hans | SVP, Business Operations | M Exercise | 2015-06-12 | 2015-06-16 | 8,300 | $0.19 | $1.6K | 19,620 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise deriv | 2015-05-28 | 2015-06-05 | 500 | — | $0 | 96,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise | 2015-05-28 | 2015-06-05 | 500 | $2.75 | $1.4K | 7,500 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | S Sale | 2015-05-28 | 2015-06-05 | 500 | $38.02 | $19.0K | 7,000 | SEC↗ |
| Schwartz Steven Daniel | Director | S Sale | 2015-05-22 | 2015-05-22 | 5,196 | $38.88 | $202.0K | 402,056 | SEC↗ |
| Schwartz Steven Daniel | Director | S Sale | 2015-05-22 | 2015-05-22 | 11,679 | $38.16 | $445.7K | 407,252 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise deriv | 2015-05-21 | 2015-05-22 | 500 | — | $0 | 96,500 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | S Sale | 2015-05-21 | 2015-05-22 | 500 | $38.87 | $19.4K | 7,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise | 2015-05-21 | 2015-05-22 | 500 | $2.75 | $1.4K | 7,500 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-05-19 | 2015-05-21 | 1,000 | $36.91 | $36.9K | 10,531 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-05-19 | 2015-05-21 | 1,000 | $36.91 | $36.9K | 10,531 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-05-19 | 2015-05-21 | 1,000 | $36.91 | $36.9K | 10,531 | SEC↗ |
| Schwartz Steven Daniel | Director | S Sale | 2015-05-08 | 2015-05-11 | 17,250 | $33.05 | $570.1K | 418,931 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise deriv | 2015-05-07 | 2015-05-08 | 500 | — | $0 | 97,500 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise | 2015-05-07 | 2015-05-08 | 500 | $2.75 | $1.4K | 7,500 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | S Sale | 2015-05-07 | 2015-05-08 | 500 | $33.28 | $16.6K | 7,000 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | S Sale | 2015-05-05 | 2015-05-07 | 25,000 | $30.00 | $750.0K | 283,988 | SEC↗ |
| Bain Linda | Chief Financial Officer | M Exercise deriv | 2015-05-04 | 2015-05-06 | 2,500 | — | $0 | 237,500 | SEC↗ |
| Hull Hans | SVP, Business Operations | M Exercise deriv | 2015-05-04 | 2015-05-06 | 5,000 | — | $0 | 22,500 | SEC↗ |
| Wachter Paul | Director | S Sale | 2015-05-04 | 2015-05-06 | 1,192 | $30.87 | $36.8K | 44,313 | SEC↗ |
| Bain Linda | Chief Financial Officer | M Exercise | 2015-05-04 | 2015-05-06 | 2,500 | $3.15 | $7.9K | 11,500 | SEC↗ |
| Bain Linda | Chief Financial Officer | S Sale | 2015-05-04 | 2015-05-06 | 2,500 | $31.59 | $79.0K | 9,000 | SEC↗ |
| Hull Hans | SVP, Business Operations | M Exercise | 2015-05-04 | 2015-05-06 | 5,000 | $0.19 | $950 | 16,320 | SEC↗ |
| Hull Hans | SVP, Business Operations | S Sale | 2015-05-04 | 2015-05-06 | 5,000 | $30.87 | $154.3K | 11,320 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-05-01 | 2015-05-05 | 20,000 | $32.37 | $647.4K | 577,989 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise deriv | 2015-04-28 | 2015-04-30 | 1,000 | — | $0 | 98,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | S Sale | 2015-04-28 | 2015-04-30 | 1,000 | $35.67 | $35.7K | 7,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise | 2015-04-28 | 2015-04-30 | 1,000 | $2.75 | $2.8K | 8,000 | SEC↗ |
| Wachter Paul | Director | S Sale | 2015-04-27 | 2015-04-29 | 1,192 | $35.61 | $42.4K | 45,505 | SEC↗ |
| Schwartz Steven Daniel | Director | S Sale | 2015-04-23 | 2015-04-23 | 16,875 | $38.62 | $651.7K | 436,181 | SEC↗ |
| Bain Linda | Chief Financial Officer | A Award deriv | 2015-04-21 | 2015-04-23 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Barone Samuel B. | Chief Medical Officer | A Award deriv | 2015-04-21 | 2015-04-23 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Blumenkranz Mark S. | Director | A Award deriv | 2015-04-21 | 2015-04-23 | 7,000 | — | $0 | 7,000 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | A Award deriv | 2015-04-21 | 2015-04-23 | 67,000 | — | $0 | 67,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise deriv | 2015-04-21 | 2015-04-23 | 1,000 | — | $0 | 99,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | A Award deriv | 2015-04-21 | 2015-04-23 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Hull Hans | SVP, Business Operations | A Award deriv | 2015-04-21 | 2015-04-23 | 23,000 | — | $0 | 23,000 | SEC↗ |
| MCLAUGHLIN JOHN PETER | Director | A Award deriv | 2015-04-21 | 2015-04-23 | 7,000 | — | $0 | 7,000 | SEC↗ |
| Rubio Roman G. | SVP, Translational Medicine | A Award deriv | 2015-04-21 | 2015-04-23 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Schwartz Steven Daniel | Director | A Award deriv | 2015-04-21 | 2015-04-23 | 7,000 | — | $0 | 7,000 | SEC↗ |
| Wachter Paul | Director | A Award deriv | 2015-04-21 | 2015-04-23 | 7,000 | — | $0 | 7,000 | SEC↗ |
| Bain Linda | Chief Financial Officer | A Award | 2015-04-21 | 2015-04-23 | 9,000 | — | $0 | 9,000 | SEC↗ |
| Barone Samuel B. | Chief Medical Officer | A Award | 2015-04-21 | 2015-04-23 | 7,000 | — | $0 | 7,000 | SEC↗ |
| Blumenkranz Mark S. | Director | A Award | 2015-04-21 | 2015-04-23 | 2,000 | — | $0 | 597,989 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | A Award | 2015-04-21 | 2015-04-23 | 23,000 | — | $0 | 308,988 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | A Award | 2015-04-21 | 2015-04-23 | 7,000 | — | $0 | 7,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | S Sale | 2015-04-21 | 2015-04-23 | 1,000 | $39.21 | $39.2K | 0 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise | 2015-04-21 | 2015-04-23 | 1,000 | $2.75 | $2.8K | 1,000 | SEC↗ |
| Hull Hans | SVP, Business Operations | A Award | 2015-04-21 | 2015-04-23 | 8,000 | — | $0 | 11,320 | SEC↗ |
| MCLAUGHLIN JOHN PETER | Director | A Award | 2015-04-21 | 2015-04-23 | 2,000 | — | $0 | 2,000 | SEC↗ |
| Rubio Roman G. | SVP, Translational Medicine | A Award | 2015-04-21 | 2015-04-23 | 7,000 | — | $0 | 7,000 | SEC↗ |
| Schwartz Steven Daniel | Director | A Award | 2015-04-21 | 2015-04-23 | 2,000 | — | $0 | 453,056 | SEC↗ |
| Wachter Paul | Director | A Award | 2015-04-21 | 2015-04-23 | 2,000 | — | $0 | 2,000 | SEC↗ |
| Wachter Paul | Director | S Sale | 2015-04-20 | 2015-04-21 | 1,192 | $40.19 | $47.9K | 46,697 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-16 | 2015-04-20 | 24,800 | $41.59 | $1.03M | 596,189 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-16 | 2015-04-20 | 200 | $42.04 | $8.4K | 595,989 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise deriv | 2015-04-14 | 2015-04-15 | 1,000 | — | $0 | 100,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise | 2015-04-14 | 2015-04-15 | 1,000 | $2.75 | $2.8K | 1,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | S Sale | 2015-04-14 | 2015-04-15 | 1,000 | $39.45 | $39.5K | 0 | SEC↗ |
| Zygtech, LLC | 10% Owner | S Sale | 2015-04-14 | 2015-04-15 | 4,600 | $39.93 | $183.7K | 2,438,176 | SEC↗ |
| Wachter Paul | Director | S Sale | 2015-04-13 | 2015-04-15 | 338 | $39.85 | $13.5K | 47,913 | SEC↗ |
| Wachter Paul | Director | S Sale | 2015-04-13 | 2015-04-15 | 830 | $39.10 | $32.5K | 48,251 | SEC↗ |
| Wachter Paul | Director | S Sale | 2015-04-13 | 2015-04-15 | 24 | $40.74 | $978 | 47,889 | SEC↗ |
| Zygtech, LLC | 10% Owner | S Sale | 2015-04-13 | 2015-04-15 | 776 | $40.69 | $31.6K | 2,442,776 | SEC↗ |
| Zygtech, LLC | 10% Owner | S Sale | 2015-04-13 | 2015-04-15 | 7,350 | $39.94 | $293.6K | 2,443,552 | SEC↗ |
| Zygtech, LLC | 10% Owner | S Sale | 2015-04-13 | 2015-04-15 | 12,274 | $39.09 | $479.8K | 2,450,902 | SEC↗ |
| Schwartz Steven Daniel | Director | S Sale | 2015-04-09 | 2015-04-13 | 17,050 | $39.72 | $677.2K | 451,256 | SEC↗ |
| Schwartz Steven Daniel | Director | S Sale | 2015-04-09 | 2015-04-13 | 200 | $40.38 | $8.1K | 451,056 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-08 | 2015-04-08 | 2,500 | $39.94 | $99.8K | 620,989 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise deriv | 2015-04-07 | 2015-04-08 | 9,000 | — | $0 | 101,000 | SEC↗ |
| Hull Hans | SVP, Business Operations | M Exercise deriv | 2015-04-07 | 2015-04-08 | 27,500 | — | $0 | 27,500 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | M Exercise | 2015-04-07 | 2015-04-08 | 9,000 | $2.75 | $24.8K | 9,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | S Sale | 2015-04-07 | 2015-04-08 | 8,708 | $38.59 | $336.0K | 292 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | S Sale | 2015-04-07 | 2015-04-08 | 292 | $39.06 | $11.4K | 0 | SEC↗ |
| Hull Hans | SVP, Business Operations | S Sale | 2015-04-07 | 2015-04-08 | 26,613 | $38.59 | $1.03M | 4,207 | SEC↗ |
| Hull Hans | SVP, Business Operations | M Exercise | 2015-04-07 | 2015-04-08 | 27,500 | $0.19 | $5.2K | 30,820 | SEC↗ |
| Hull Hans | SVP, Business Operations | S Sale | 2015-04-07 | 2015-04-08 | 887 | $39.06 | $34.6K | 3,320 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-07 | 2015-04-08 | 32 | $39.06 | $1.2K | 11,531 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-07 | 2015-04-08 | 968 | $38.59 | $37.4K | 11,563 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-07 | 2015-04-08 | 32 | $39.06 | $1.2K | 11,531 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-07 | 2015-04-08 | 968 | $38.59 | $37.4K | 11,563 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-07 | 2015-04-08 | 32 | $39.06 | $1.2K | 11,531 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-07 | 2015-04-08 | 21,774 | $38.59 | $840.3K | 624,215 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-07 | 2015-04-08 | 968 | $38.59 | $37.4K | 11,563 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-04-07 | 2015-04-08 | 726 | $39.06 | $28.4K | 623,489 | SEC↗ |
| Blumenkranz Mark S. | Director | S Sale | 2015-01-13 | 2015-01-15 | 100,000 | $55.46 | $5.55M | 645,989 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | S Sale | 2015-01-13 | 2015-01-15 | 85,000 | $55.46 | $4.71M | 285,988 | SEC↗ |
| Schwartz Steven Daniel | Director | S Sale | 2015-01-13 | 2015-01-15 | 91,000 | $55.46 | $5.05M | 468,306 | SEC↗ |
| Wachter Paul | Director | S Sale | 2015-01-13 | 2015-01-15 | 14,000 | $55.46 | $776.4K | 49,081 | SEC↗ |
| Zygtech, LLC | 10% Owner | S Sale | 2015-01-13 | 2015-01-15 | 100,000 | $55.46 | $5.55M | 2,463,176 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | M Exercise deriv | 2014-12-12 | 2015-01-14 | 413 | — | $0 | 159,587 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | M Exercise | 2014-12-12 | 2015-01-14 | 413 | $0.21 | $87 | 371,401 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | G Gift | 2014-12-12 | 2015-01-14 | 413 | — | $0 | 370,988 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | G Gift | 2014-12-12 | 2015-01-14 | 413 | — | $0 | 413 | SEC↗ |
| Rubio Roman G. | SVP, Translational Medicine | A Award deriv | 2014-10-03 | 2014-11-14 | 180,000 | — | $0 | 180,000 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | C Conversion deriv | 2014-08-05 | 2014-08-05 | 147,410 | — | $0 | 0 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | C Conversion deriv | 2014-08-05 | 2014-08-05 | 531,208 | — | $0 | 0 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | C Conversion deriv | 2014-08-05 | 2014-08-05 | 184,594 | — | $0 | 0 | SEC↗ |
| REGENERON PHARMACEUTICALS INC | 10% Owner | C Conversion deriv | 2014-08-05 | 2014-08-05 | 689,655 | — | $0 | 0 | SEC↗ |
| REGENERON PHARMACEUTICALS INC | 10% Owner | C Conversion deriv | 2014-08-05 | 2014-08-05 | 531,208 | — | $0 | 0 | SEC↗ |
| Blumenkranz Mark S. | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 25,000 | — | $0 | 0 | SEC↗ |
| Blumenkranz Mark S. | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 5,689 | — | $0 | 0 | SEC↗ |
| Blumenkranz Mark S. | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 5,689 | $1.45 | $8.2K | 20,989 | SEC↗ |
| Blumenkranz Mark S. | Director | C Conversion deriv | 2014-08-05 | 2014-08-07 | 20,989 | — | $0 | 0 | SEC↗ |
| Blumenkranz Mark S. | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 4,137 | — | $0 | 0 | SEC↗ |
| Blumenkranz Mark S. | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 4,137 | $1.45 | $6.0K | 12,531 | SEC↗ |
| Blumenkranz Mark S. | Director | C Conversion deriv | 2014-08-05 | 2014-08-07 | 12,531 | — | $0 | 0 | SEC↗ |
| Blumenkranz Mark S. | Director | C Conversion deriv | 2014-08-05 | 2014-08-07 | 12,531 | — | $0 | 0 | SEC↗ |
| Blumenkranz Mark S. | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 4,137 | $1.45 | $6.0K | 12,531 | SEC↗ |
| Blumenkranz Mark S. | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 4,137 | — | $0 | 0 | SEC↗ |
| Blumenkranz Mark S. | Director | C Conversion deriv | 2014-08-05 | 2014-08-07 | 12,531 | — | $0 | 0 | SEC↗ |
| Blumenkranz Mark S. | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 4,137 | $1.45 | $6.0K | 12,531 | SEC↗ |
| Blumenkranz Mark S. | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 4,137 | — | $0 | 0 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | X Exercise deriv | 2014-08-05 | 2014-08-07 | 3,102 | — | $0 | 0 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | X Exercise deriv | 2014-08-05 | 2014-08-07 | 3,102 | $1.45 | $4.5K | 10,988 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | C Conversion deriv | 2014-08-05 | 2014-08-07 | 10,988 | — | $0 | 0 | SEC↗ |
| Hull Hans | SVP, Legal and Corp. Dev. | C Conversion deriv | 2014-08-05 | 2014-08-07 | 3,320 | — | $0 | 0 | SEC↗ |
| MCLAUGHLIN JOHN PETER | Director | C Conversion deriv | 2014-08-05 | 2014-08-07 | 13,280 | — | $0 | 0 | SEC↗ |
| MCLAUGHLIN JOHN PETER | Director | C Conversion deriv | 2014-08-05 | 2014-08-07 | 13,280 | — | $0 | 0 | SEC↗ |
| Schwartz Steven Daniel | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 6,620 | — | $0 | 0 | SEC↗ |
| Schwartz Steven Daniel | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 34,000 | — | $0 | 0 | SEC↗ |
| Schwartz Steven Daniel | Director | X Exercise deriv | 2014-08-05 | 2014-08-07 | 6,620 | $1.45 | $9.6K | 25,306 | SEC↗ |
| Schwartz Steven Daniel | Director | C Conversion deriv | 2014-08-05 | 2014-08-07 | 25,306 | — | $0 | 0 | SEC↗ |
| Wachter Paul | Director | C Conversion deriv | 2014-08-05 | 2014-08-07 | 63,081 | — | $0 | 0 | SEC↗ |
| Zygtech, LLC | 10% Owner | C Conversion deriv | 2014-08-05 | 2014-08-07 | 295,115 | — | $0 | 0 | SEC↗ |
| Zygtech, LLC | 10% Owner | C Conversion deriv | 2014-08-05 | 2014-08-07 | 2,799,269 | — | $0 | 0 | SEC↗ |
| Hove Anders D | 10% Owner | C Conversion deriv | 2014-08-05 | 2014-08-07 | 1,965,471 | — | $0 | 0 | SEC↗ |
| VHCP Co-Investment Holdings II | 10% Owner | C Conversion deriv | 2014-08-05 | 2014-08-07 | 1,965,471 | — | $0 | 0 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 22,400 | $26.14 | $585.5K | 441,200 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 10,100 | $27.54 | $278.2K | 418,800 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 177,700 | $26.42 | $4.69M | 408,700 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 15,100 | $25.79 | $389.4K | 231,000 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 7,900 | $25.52 | $201.6K | 215,900 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 163,300 | $25.41 | $4.15M | 208,000 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 44,700 | $17.00 | $759.9K | 44,700 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 34,223 | $17.00 | $581.8K | 181,633 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 42,700 | $17.00 | $725.9K | 227,294 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | C Conversion | 2014-08-05 | 2014-08-05 | 531,208 | — | $0 | 531,208 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | C Conversion | 2014-08-05 | 2014-08-05 | 147,410 | — | $0 | 147,410 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | C Conversion | 2014-08-05 | 2014-08-05 | 184,594 | — | $0 | 184,594 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 31,650 | $24.57 | $777.6K | 627,267 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 49,981 | $26.35 | $1.32M | 595,617 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 40,400 | $26.35 | $1.06M | 481,600 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 25,600 | $24.57 | $629.0K | 507,200 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 55,300 | $17.00 | $940.1K | 55,300 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 201,972 | $25.41 | $5.13M | 257,272 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 9,800 | $25.52 | $250.1K | 267,072 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 18,700 | $25.79 | $482.3K | 285,772 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 219,864 | $26.42 | $5.81M | 505,636 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 12,400 | $27.54 | $341.5K | 518,036 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 27,600 | $26.14 | $721.5K | 545,636 | SEC↗ |
| Deerfield Special Situations F | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 123,077 | $17.00 | $2.09M | 654,285 | SEC↗ |
| REGENERON PHARMACEUTICALS INC | 10% Owner | C Conversion | 2014-08-05 | 2014-08-05 | 531,208 | — | $0 | 1,220,863 | SEC↗ |
| REGENERON PHARMACEUTICALS INC | 10% Owner | P Buy | 2014-08-05 | 2014-08-05 | 588,235 | $17.00 | $10.00M | 1,809,098 | SEC↗ |
| REGENERON PHARMACEUTICALS INC | 10% Owner | C Conversion | 2014-08-05 | 2014-08-05 | 689,655 | — | $0 | 689,655 | SEC↗ |
| Blumenkranz Mark S. | Director | C Conversion | 2014-08-05 | 2014-08-07 | 20,989 | — | $0 | 745,989 | SEC↗ |
| Blumenkranz Mark S. | Director | X Exercise | 2014-08-05 | 2014-08-07 | 25,000 | $0.15 | $3.8K | 725,000 | SEC↗ |
| Blumenkranz Mark S. | Director | C Conversion | 2014-08-05 | 2014-08-07 | 12,531 | — | $0 | 12,531 | SEC↗ |
| Blumenkranz Mark S. | Director | C Conversion | 2014-08-05 | 2014-08-07 | 12,531 | — | $0 | 12,531 | SEC↗ |
| Blumenkranz Mark S. | Director | C Conversion | 2014-08-05 | 2014-08-07 | 12,531 | — | $0 | 12,531 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | C Conversion | 2014-08-05 | 2014-08-07 | 10,988 | — | $0 | 370,988 | SEC↗ |
| Hull Hans | SVP, Legal and Corp. Dev. | C Conversion | 2014-08-05 | 2014-08-07 | 3,320 | — | $0 | 3,320 | SEC↗ |
| MCLAUGHLIN JOHN PETER | Director | C Conversion | 2014-08-05 | 2014-08-07 | 13,280 | — | $0 | 13,280 | SEC↗ |
| MCLAUGHLIN JOHN PETER | Director | C Conversion | 2014-08-05 | 2014-08-07 | 13,280 | — | $0 | 13,280 | SEC↗ |
| Schwartz Steven Daniel | Director | X Exercise | 2014-08-05 | 2014-08-07 | 34,000 | $0.15 | $5.1K | 534,000 | SEC↗ |
| Schwartz Steven Daniel | Director | C Conversion | 2014-08-05 | 2014-08-07 | 25,306 | — | $0 | 559,306 | SEC↗ |
| Wachter Paul | Director | C Conversion | 2014-08-05 | 2014-08-07 | 63,081 | — | $0 | 63,081 | SEC↗ |
| Zygtech, LLC | 10% Owner | C Conversion | 2014-08-05 | 2014-08-07 | 295,115 | — | $0 | 3,094,384 | SEC↗ |
| Zygtech, LLC | 10% Owner | C Conversion | 2014-08-05 | 2014-08-07 | 2,799,269 | — | $0 | 2,799,269 | SEC↗ |
| Hove Anders D | 10% Owner | C Conversion | 2014-08-05 | 2014-08-07 | 1,965,471 | — | $0 | 1,965,471 | SEC↗ |
| Hove Anders D | 10% Owner | P Buy | 2014-08-05 | 2014-08-07 | 400,000 | $17.00 | $6.80M | 2,365,471 | SEC↗ |
| VHCP Co-Investment Holdings II | 10% Owner | P Buy | 2014-08-05 | 2014-08-07 | 400,000 | $17.00 | $6.80M | 2,365,471 | SEC↗ |
| VHCP Co-Investment Holdings II | 10% Owner | C Conversion | 2014-08-05 | 2014-08-07 | 1,965,471 | — | $0 | 1,965,471 | SEC↗ |
| Hull Hans | SVP, Legal and Corp. Dev. | A Award deriv | 2014-07-30 | 2014-08-01 | 75,000 | — | $0 | 75,000 | SEC↗ |
| MCLAUGHLIN JOHN PETER | Director | A Award deriv | 2014-07-30 | 2014-08-01 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Gasmi Mehdi | VP, Pharmaceutical Developme | A Award deriv | 2014-07-30 | 2014-08-01 | 70,000 | — | $0 | 70,000 | SEC↗ |
| Wachter Paul | Director | A Award deriv | 2014-07-30 | 2014-08-01 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Chalberg Thomas W. | Chief Executive Officer | A Award deriv | 2014-07-30 | 2014-08-01 | 80,000 | — | $0 | 80,000 | SEC↗ |